A population-based case-control study involving 24 657 case-control pairs, revealed a marginal increase in the risk of PCa for patients using RASi in comparison to their RASi-naïve counterparts (odds ratio [OR] 1.16) [25]. The gene discussed is MMP19; the disease is posterior cortical atrophy.